Elasmogen has been featured in BBSRC's report highlighting a few spinout companies that exemplify BBSRC investments in research.

Elasmogen has been nominated for a Life Science Award with Almac Discovery in the Innovative Collaboration category. The finalists in the Innovative Collaboration award, sponsored by @MarksClerkScot are announced! They are @ElasmogenLtd , @iCAIRD_Scot , and...

Funding from Deepbridge Capital will support development of next generation biologics January 10th 2020: Aberdeen, Scotland:  Elasmogen Ltd, the biopharmaceutical company leading the development of soloMERTM biologics, today announced it has secured follow-on equity...

We are delighted that The Times has featured Elasmogen in an article titled 'Ruthless killers? Shark antibodies are latest weapon in fight against cancer'.

Elasmogen's CEO, Caroline Barelle is featured in Converge's podcast where she discusses her business journey.

CIOLook, is currently running a special edition on most prominent women leaders and Elasmogen's CEO, Caroline Barelle has given an interview giving her perspective on leadership in the biotech industry. You can read the profile here. BioBeat has featured Caroline...

Elasmogen's CEO Dr Caroline Barelle has been featured in Insight Success special edition Successful Women Making a Difference in Biotech. The article can be read here.  ...

Biotech media outlet Labiotech.eu which covers the European Biotech industry, has today, 21 May 2019, listed Elasmogen CEO, Dr Caroline Barelle among top 20 women in leading biotech roles in Europe. The full article can be found...

Elasmogen is delighted to announce that shortlisted finalists for the 2019 BBSRC Innovator of the Year award include our CEO, Dr Caroline Barelle. The BBSRC Innovator of the Year award recognises the full breadth of impacts that BBSRC investments in research have...

Craigavon, N.I., UK, 20 Mar 2019 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Elasmogen a biotech company developing next generation therapeutic biologics, today...

Life Sciences Scotland have interviewed Elasmogen's CEO Caroline Barelle as part of their Insight series. The article can be accessed here.

Novel soloMER based albumin binder will be used for two therapeutic fusion proteins™ Aberdeen, Scotland and Seoul, Korea; January 7th 2019:  Elasmogen Ltd, developer of next generation soloMER biologics, announced today that ImmunoForge has entered a license agreement...